7 months ago
3
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has adopted a affirmative sentiment recommending selling authorisation successful the European markets for AVT03, the biosimilar campaigner for which Dr. Reddy’s Laboratories had past twelvemonth entered into a licence and proviso statement with Alvotech.
AVT03 is biosimilar of Amgen’s Prolia and Xgeva (both are denosumab successful antithetic presentations). The CHMP affirmative sentiment volition present beryllium reviewed by the European Commission, pursuing which a determination volition beryllium made connected the assistance of selling authorisation successful the European Economic Area, which includes the European Union subordinate countries, successful summation to Norway, Iceland and Liechtenstein. A selling authorisation exertion (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA) volition beryllium made separately, Dr. Reddy’s said connected Monday.
Dr. Reddy’s and Alvotech had successful May 2024 entered into a licence and proviso statement for the commercialisation of AVT03. Under the agreement, Alvotech volition make and manufacture AVT03, portion Dr. Reddy’s is liable for registration and commercialisation successful applicable markets, including the U.S. and Europe. Dr. Reddy’s commercialization rights are exclusive for the U.S., and semi-exclusive for Europe and the U.K. Upon approval, Dr. Reddy’s volition connection the biosimilar nether the tradenames Acvybra (denosumab) 60 mg/mL solution for injection successful a pre-filled syringe and Xbonzy (denosumab) 70 mg/mL solution for injection successful a vial, the institution said.
Prolia is utilized to dainty osteoporosis successful women who person been done menopause and successful men who are astatine accrued hazard of fractures, bony nonaccomplishment linked to hormone ablation successful men with prostate cancer. Xgeva is indicated to forestall bony complications successful adults with precocious crab involving bony and for attraction of adults and skeletally mature adolescents with elephantine compartment tumour of bone, the institution said successful a release.
